Amgen (AMGN) announced new data supporting Repatha's efficacy. The data were presented at the European Society of Cardiology Congress in Rome. The analysis showed that treatment with Repatha (140 mg every two weeks or 420 mg once per month) reduced LDL-C levels and other lipids from baseline to the mean of Weeks 10 and 12 across all risk groups compared to placebo or ezetimibe. In the very high-risk group, for example, treatment with Repatha lowered LDL-C 65.2% more that placebo and 40.7% more than Zetia. The overall rates of adverse events for Repatha, Zetia and placebo were 43.1%, 50.5% and 40;8%, respectively.